AT1-receptor blocker-based combination therapy in hypertension

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Nephrology

Background:

• Hypertension remains a global health challenge, with many patients failing to achieve target blood pressure control despite treatment.
• Combination therapy with complementary mechanisms, like angiotensin II receptor blockers (ARBs) and diuretics, is crucial for managing resistant hypertension.

Purpose of the Study:

• To evaluate the efficacy and tolerability of a fixed-dose combination of candesartan cilexetil-hydrochlorothiazide (HCT) 16/12.5 mg in patients with hypertension.
• To compare the antihypertensive effects of candesartan cilexetil-HCT with monotherapy and another ARB-diuretic combination.

Main Methods:

• Clinical trials involving patients with mild-to-moderate and mild, moderate, or severe hypertension.
• Double-blind, randomized studies comparing candesartan cilexetil-HCT 16/12.5 mg against monotherapy and losartan-HCT 50/12.5 mg.

Main Results:

• Candesartan cilexetil-HCT 16/12.5 mg demonstrated significantly greater efficacy than monotherapy in patients with mild-to-moderate hypertension.
• The combination was more effective than losartan-HCT 50/12.5 mg in patients with varying degrees of hypertension.
• Antihypertensive effects of candesartan cilexetil-HCT persisted for up to 48 hours, unlike the rapid decline observed with losartan-HCT.

Conclusions:

• The fixed-dose combination of candesartan cilexetil-HCT 16/12.5 mg offers enhanced efficacy and excellent tolerability for hypertension management.
• This combination represents a new standard of care for patients requiring more than monotherapy for blood pressure control.